Aspirin for Prevention of Preeclampsia in Healthy, Nulliparous Obese and Overweight Pregnant Women

Preterm preeclampsia is an important cause of maternal and perinatal death and complications. It is uncertain whether the intake of low‐dose aspirin during pregnancy reduces the risk of preterm preeclampsia. In a meta‐analysis of individual‐participant data from the trials, the effect of aspirin was not affected by the gestational age at the onset of therapy. In contrast, other meta‐analyses showed that aspirin started at or before 16 weeks of gestation resulted in halving the rates of preeclampsia, fetal growth restriction, and perinatal death, whereas aspirin started after 16 weeks of gestation did not have a significant benefit. In addition, the beneficial effect of aspirin that was started at or before 16 weeks of gestation was dose‐dependent, with a greater reduction in the incidence of preeclampsia being associated with a daily dose of aspirin of 100 mg or more. This will be a randomized control trial to estimate the efficacy of two doses (81 mg versus 162 mg) of aspirin for prevention of preeclampsia in healthy, nulliparous obese and overweight pregnant women identified in the first trimester.